VA/DoD 2025 Obesity Guidelines Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. This effort involved a multidisciplinary panel https://t.co/ukuKGCHhOf

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/VfV873Lire

Obesity as a Risk Factor for Rheumatic Diseases https://t.co/zTEHDbTGjb https://t.co/1JuGAfL5oK

The Need for Weight Loss and Weight Gain in the ILD Clinic https://t.co/UaKW9GPJTN https://t.co/QGYblSxbfP

Beyond Disease Modification: Palliative Care in Rheumatology Palliative care is often mistakenly equated to hospice and end of life care. While this is an important subset of the field, it does not capture its broader impacts and tenets. https://t.co/VcP1x1nKqp https://t.co/DnkdsmgG1x

Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/qSXZkyYTmZ

Retrospective study from India on 157 juvenile dermatomyositis (JDM) pts - 44 (28%) had calcinosis. They had a long Dx delay (12 mos), were NXP2+ in 41%, & high risk for Lipodystrophy (39% vs 5%). 39% improved while 61% had static/progressive Dz https://t.co/z5gvqzZV6C https://t.co/9WlzPDZ74w

Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to https://t.co/9dfmKLuJF7

BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001).  1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/BoSgFoOyNN

52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru

Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/OBMdjsegIq

Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/OYTXD4KV6O

Long-term F/U of T2T Artic trial. 230 DMARD naive pts, 84% ACPA+ 179 (82%) in 10 yr F/U & 82% were in DAS < 1.6 remission 10 yrs later w/ only 17% w/ Xray progression. ~50% on csDMARDs, 30% on bDMARDs. Early aggressive works! https://t.co/ASRrIZqfS5 https://t.co/SykEI4QjPa

Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. https://t.co/xPctEjFCLT https://t.co/YIHFaQkzeO